January 2025 in “SKIN The Journal of Cutaneous Medicine” This study of baricitinib in adults with severe alopecia areata found that after initial success, 10.9% of participants lost treatment response by Week 152. Factors like longer disease duration and severe baseline symptoms were more common in those losing response.
51 citations
,
March 1987 in “Journal of The American Academy of Dermatology” This study found that twice-daily application of 3% topical minoxidil maintained a higher nonvellus hair count compared to once-daily application over 2 years and 9 months in men with male pattern baldness.
2 citations
,
September 2022 in “Dermatologic Therapy” In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.
May 2024 in “Journal of the Egyptian Womenʼs Dermatologic Society” This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.
December 2025 in “FEBS Open Bio” In this study, fibroblasts from long-term skin biopsy cultures retained their ability to reprogram into induced pluripotent stem cells after 16 months, despite undergoing transcriptional changes and decreased proliferation rates over successive generations.